| Schedule of financial information by reportable segment |
The following is financial information relating to the Company's reportable segments (in thousands):
|
|
|
|
|
|
|
|
|
For the Quarter Ended September 30, 2025 |
|
|
Protein Sciences |
|
|
Diagnostics and Spatial Biology |
|
|
Total |
Net sales |
$ |
202,188 |
|
$ |
79,458 |
|
$ |
281,646 |
Other revenue(1) |
|
|
|
|
|
|
|
5,439 |
Intersegment |
|
|
|
|
|
|
|
(530) |
Consolidated net sales |
|
|
|
|
|
|
$ |
286,555 |
Segment operating income |
|
|
|
|
|
|
|
|
Cost of sales |
|
50,518 |
|
|
33,737 |
|
|
|
Selling, general and administrative |
|
59,766 |
|
|
27,851 |
|
|
|
Research and development |
|
14,191 |
|
|
8,992 |
|
|
|
Segment operating income |
$ |
77,713 |
|
$ |
8,878 |
|
$ |
86,591 |
Unallocated amounts |
|
|
|
|
|
|
|
|
Amortization of intangibles |
|
|
|
|
|
|
|
(15,350) |
Acquisition related expenses and other |
|
|
|
|
|
|
|
(3,351) |
Certain litigation charges |
|
|
|
|
|
|
|
(2,408) |
Stock based compensation, inclusive of employer taxes |
|
|
|
|
|
|
|
(12,096) |
Restructuring and restructuring-related costs |
|
|
|
|
|
|
|
(7,511) |
Recovery of assets held-for-sale |
|
|
|
|
|
|
|
6,789 |
Corporate general, selling, and administrative expenses |
|
|
|
|
|
|
|
(2,433) |
Impact of business held-for-sale(1) |
|
|
|
|
|
|
|
(2,573) |
Consolidated operating income |
|
|
|
|
|
|
$ |
47,658 |
(1)Includes the quarterly results of a business that has met the held-for-sale criteria as of June 30, 2025.
|
|
|
|
|
|
|
|
|
For the Quarter Ended September 30, 2024 |
|
|
Protein Sciences |
|
|
Diagnostics and Spatial Biology |
|
|
Total |
Net sales |
$ |
204,535 |
|
$ |
83,192 |
|
$ |
287,727 |
Other revenue(1) |
|
|
|
|
|
|
|
2,303 |
Intersegment |
|
|
|
|
|
|
|
(572) |
Consolidated net sales |
|
|
|
|
|
|
$ |
289,458 |
Segment operating income |
|
|
|
|
|
|
|
|
Cost of sales |
|
52,498 |
|
|
35,633 |
|
|
|
Selling, general and administrative |
|
57,132 |
|
|
33,518 |
|
|
|
Research and development |
|
14,364 |
|
|
9,764 |
|
|
|
Segment operating income |
$ |
80,541 |
|
$ |
4,277 |
|
$ |
84,818 |
Unallocated amounts |
|
|
|
|
|
|
|
|
Amortization of intangibles |
|
|
|
|
|
|
|
(19,741) |
Acquisition related expenses and other |
|
|
|
|
|
|
|
(1,701) |
Certain litigation charges |
|
|
|
|
|
|
|
(292) |
Stock based compensation, inclusive of employer taxes |
|
|
|
|
|
|
|
(10,637) |
Restructuring and restructuring-related costs |
|
|
|
|
|
|
|
(11,022) |
Corporate general, selling, and administrative expenses |
|
|
|
|
|
|
|
(1,586) |
Impact of business held-for-sale(1) |
|
|
|
|
|
|
|
148 |
Consolidated operating income |
|
|
|
|
|
|
$ |
39,987 |
(1)Includes the quarterly results of a business that has met the held-for-sale criteria as of December 31, 2023.
|